ELOQUENT-2: Elotuzumab for relapsed/refractory multiple myeloma - European Medical Journal

ELOQUENT-2: Elotuzumab for relapsed/refractory multiple myeloma

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now